Finanznachrichten11d
DelveInsight Business Research, LLP: ROZLYTREK's Market Growth Reflects Transforming Treatment for NTRK and ROS1-Positive Cancers | DelveInsight
Entrectinib has demonstrated both in vitro and in vivo efficacy in inhibiting cancer cell lines across multiple tumor types carrying NTRK, ROS1, or ALK fusions. Additionally, it achieves steady ...
National Institute for Health and Care Excellence24d
Awaiting development: Guidance and quality standards
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines [ID6356] Technology appraisal guidance Repotrectinib for treating NTRK fusion-positive advanced ...
National Institute for Health and Care Excellence23d
Awaiting development: Guidance and quality standards
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949] Technology appraisal guidance Istradefylline with levodopa ...
Targeted Oncology25d
Advancing Stem Cell Therapy and Equity in Patient Care
Jeff Auletta, MD, discusses his key takeaways from the 2025 Transplant and Cellular Therapy Meetings. Jeff Auletta, MD, senior vice president of health equity at the National Marrow Donor Program and ...